An observational study in Hypertension, Pulmonary Arterial, sponsored by Hospital Italiano de Buenos Aires. Recruiting at 1 site in Argentina. Open to participants aged 17 Years and older. Per ClinicalTrials.gov, last updated 2025-08-24.
Sponsored by Hospital Italiano de Buenos Aires · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Pulmonary Arterial Hypertension with a site in Argentina — 7 open to participants now, 11 under way, 7 of them phase 3. Pulmonary Arterial Hypertension · Argentina.
Among the 42 studies in Pulmonary Arterial Hypertension with a site in Argentina, this one is one of 2 that started in 2017, is one of 2 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 13th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →7 of the 42 studies in Pulmonary Arterial Hypertension with a site in Argentina are open now. Recruiting first, the newest first:
Insmed Incorporated · Sites in Argentina, United States, Australia and 5 more countries
Ages 18–75
Inhibikase Therapeutics · Sites in Argentina, United States, Australia and 11 more countries
Ages 18–75
Novartis Pharmaceuticals · Sites in Argentina, United States, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
Gossamer Bio USA, Inc. · Sites in Argentina, United States, Australia and 27 more countries
Ages 18–75
AOP Orphan Pharmaceuticals AG · Sites in Argentina, Austria, Czechia and 9 more countries
Ages 18–75
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 17 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 11 · Phase 3 29 · Phase 4 3
First in 2003; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 291 across the 40 interventional studies, 152 across the 2 observational. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 42 have an industry lead sponsor. The 10 most frequent:
Hospital Italiano de Buenos Aires is the lead sponsor of 134 studies on the registry; 24 are open to participants now.
Hospital Italiano de Buenos Aires has 1 study filed under Pulmonary Arterial Hypertension — fewer than ten, so there is no comparison to draw.
4 of the studies in Pulmonary Arterial Hypertension with a site in Argentina that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06274801Phase 3Gossamer Bio USA, Inc.Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) | 2026-12 |
| NCT05649748Phase 3Insmed IncorporatedAn Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | 2026-12-31 |
| NCT06317805AOP Orphan Pharmaceuticals AGInitial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 42 studies in Pulmonary Arterial Hypertension with a site in Argentina, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.
The Institutional Registry of Pulmonary Hypertension includes patients prospectively with incident pulmonary hypertension type I. It also includes prevalent cases from our HMO who had diagnosis prior the beginning of the registry.
Patients who meet inclusion criteria and none of exclusion criteria during the study period are eligible to this study. In the population, the PAH cohort will consist of those incident cases and prevalent cases PAH WHO group 1 aged ≥18 years between January 2017 and December 2030 who attended at Hospital Italiano of Buenos Aires.
Inclusion Criteria:
Pulmonary Hypertension prevalence
Pulmonary Hypertension prevalence in our community.
Time frame: 1 year
Pulmonary Hypertension incidence
Pulmonary Hypertension incidence in our community
Time frame: 1 year
Mortality rate
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2017 (actual). Primary completion is estimated for Dec 2030, 167 months after the start.
Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 167 months is above that.
Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension →
Hospital Italiano de Buenos Aires →